Case Report

Split Viewer

Blood Res 2015; 50(1):

Published online March 31, 2015

https://doi.org/10.5045/br.2015.50.1.51

© The Korean Society of Hematology

HBV reactivation in a HBsAg-negative patient with multiple myeloma treated with prednisolone maintenance therapy after autologous HSCT

Ha Ra Gu, Dong-Yeop Shin, Hong Seok Choi, Chae Ho Moon, Su Cheol Park, and Hye Jin Kang*

Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.

Correspondence to : Correspondence to Hye Jin Kang, M.D. Division of Hematology/Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, 75 Nowon-gil, Nowon-gu, Seoul 139-706, Korea. Tel: +82-2-970-1289, Fax: +82-2-970-2410, hyejin@kcch.re.kr

Received: March 12, 2013; Revised: April 15, 2013; Accepted: January 9, 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Hepatitis B virus (HBV) reactivation has previously occurred in hepatitis B surface antigen-negative patients with malignant lymphoma who received rituximab-based combination chemotherapy. However, few reports have described cases of HBV reactivation in patients with multiple myeloma thus far. We report a case of HBV reactivation in a patient with multiple myeloma treated with chemotherapy, autologous hematopoietic stem cell transplantation, and maintenance steroid therapy. For the HBV reactivation, the patient was treated with the antiviral agent entecavir. The clinical symptoms and laboratory findings improved after 3 months. Further studies should target the identification of patients at high risk of HBV reactivation in multiple myeloma treated with autologous hematopoietic stem cell transplantation and steroid therapy for maintenance and establish viral prophylaxis strategies, especially in Korea, in which HBV infection is endemic.

Keywords HBV reactivation, Multiple myeloma, Transplantation, Prednisolone, Chemotherapy

Article

Case Report

Blood Res 2015; 50(1): 51-53

Published online March 31, 2015 https://doi.org/10.5045/br.2015.50.1.51

Copyright © The Korean Society of Hematology.

HBV reactivation in a HBsAg-negative patient with multiple myeloma treated with prednisolone maintenance therapy after autologous HSCT

Ha Ra Gu, Dong-Yeop Shin, Hong Seok Choi, Chae Ho Moon, Su Cheol Park, and Hye Jin Kang*

Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.

Correspondence to: Correspondence to Hye Jin Kang, M.D. Division of Hematology/Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, 75 Nowon-gil, Nowon-gu, Seoul 139-706, Korea. Tel: +82-2-970-1289, Fax: +82-2-970-2410, hyejin@kcch.re.kr

Received: March 12, 2013; Revised: April 15, 2013; Accepted: January 9, 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Hepatitis B virus (HBV) reactivation has previously occurred in hepatitis B surface antigen-negative patients with malignant lymphoma who received rituximab-based combination chemotherapy. However, few reports have described cases of HBV reactivation in patients with multiple myeloma thus far. We report a case of HBV reactivation in a patient with multiple myeloma treated with chemotherapy, autologous hematopoietic stem cell transplantation, and maintenance steroid therapy. For the HBV reactivation, the patient was treated with the antiviral agent entecavir. The clinical symptoms and laboratory findings improved after 3 months. Further studies should target the identification of patients at high risk of HBV reactivation in multiple myeloma treated with autologous hematopoietic stem cell transplantation and steroid therapy for maintenance and establish viral prophylaxis strategies, especially in Korea, in which HBV infection is endemic.

Keywords: HBV reactivation, Multiple myeloma, Transplantation, Prednisolone, Chemotherapy

Fig 1.

Figure 1.

Changes in the liver function panel after entecavir treatment.

Blood Research 2015; 50: 51-53https://doi.org/10.5045/br.2015.50.1.51
Blood Res
Volume 59 2024

Stats or Metrics

Share this article on

  • line

Related articles in BR

Blood Research

pISSN 2287-979X
eISSN 2288-0011
qr-code Download